Article information
Full text is only aviable in PDF
Bibliografía
[1.]
V. Kapur, T.S. Whittam, J.M. Musser.
Is Mycobacterium tuberculosis 15000 years old?.
J Infect Dis, 170 (1994), pp. 1348-1349
[2.]
J. Hayman.
Mycobacterium ulcerans: an infection from Jurasic time?.
Lancet, 2 (1984), pp. 1015-1016
[3.]
T.M. Daniel.
The origins and precolonial epidemiology of tuberculosis in the Americas: can we figure them out?.
Int J Tuberc Lung Dis, 4 (2000), pp. 395-400
[4.]
W.W. Stead, K.D. Eisenah, M.D. Cave, M.L. Beggs, G.L. Templeton, C.O. Thoen, et al.
When did Mycobacterium tuberculosis infection first occur in the new world? An important question with public health implications.
Am J Respir Crit Care Med, 151 (1995), pp. 1267-1268
[5.]
R. Hare.
The antiquity of diseases caused by bacteria and viruses. A review of the problem from a bacteriologist's point of view.
Diseases in antiquity. A survey of the diseases, injuries and surgery of early populations, pp. 115-131
[6.]
J.H. Bates, W.W. Stead.
The history of tuberculosis as a global epidemic.
Med Clin North Am, 77 (1993), pp. 1205-1217
[7.]
F. Haas, S.S. Haas.
The origins of Mycobacterium tuberculosis and the notion of its contagiousness.
Tuberculosis, pp. 3-19
[8.]
World Health Organization.
Global tuberculosis control.
WHO Report 1999,
[9.]
World Health Organization.
Anti-tuberculosis drug resistance in the world: The WHO / IUATLD global project on anti-tuberculosis drug resistance surveillance 1994-1997.
Who/Tb/97.229,
[10.]
A. Pablos-Méndez, M.C. Raviglione, A. Laszlo, N. Binkin, H.L. Rieder, F. Bustreo, et al.
Global surveillance for anti-tuberculosis drug resistance, 1994-1997.
N Engl J Med, 338 (1998), pp. 1641-1649
[11.]
World Health Organization.
WHO report on the tuberculosis epidemic.
Who/Tb/97.224,
[12.]
J.A. Caminero.
Resistencia primaria a fármacos antituberculosos.
Med Clin (Barc), 93 (1989), pp. 30-36
[13.]
Committee on Treatment of International Union Against Tuberculosis (IUAT).
Probability of drug resistant.
Documents prepared by the Committee on Treatment of IUAT. París,, (1975),
[15.]
J.M. Musser.
Antimicrobial agent resistance in mycobacteria: molecular genetic insights.
Clin Microbiol Rev, 8 (1995), pp. 496-514
[16.]
P.F. Riska, J.r. Jacobs WR, D. Alland.
Molecular determinants of drug resistance in tuberculosis.
Int J Tuberc Lung Dis, 4 (2000), pp. S4-S10
[17.]
W.W. Yew, C.H. Chau.
Drug resistant tuberculosis in the 1990s.
Eur Respir J, 8 (1995), pp. 1184-1192
[18.]
D.A. Mitchison.
Drug resistance in mycobacteria.
Br Med J, 40 (1984), pp. 84-90
[19.]
V. Ausina.
Tuberculosis multirresistente. Puntualizaciones y reflexiones sobre un tema polémico y de candente actualidad.
Med Clin (Barc), 106 (1996), pp. 15-18
[20.]
W. Fox, G.A. Ellard, D.A. Mitchison.
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Unit, 1946-1986, with relevant subsequent publications.
Int J Tuberc Lung Dis, 3 (1999), pp. S231-S279
[21.]
R. Cowley, R. Briney.
Primary drug resistant tuberculosis in Vietnam veterans.
Am Rev Respir Dis, 101 (1970), pp. 703
[22.]
S.J. Kim, S.C. Kim, G.H. Bai.
Drug resistance Mycobacterium tuberculosis isolated from patients with pulmonary tuberculosis discovered in the fourth nation-wide tuberculosis prevalence survey in 1980 in Korea.
Tuberc Respir Dis (Korean), 29 (1982), pp. 1-10
[23.]
D.A. Mitchison, A.J. Nunn.
Influence of initial drug resistance as the response to short-course chemotherapy of pulmonary tuberculosis.
Am Rev Respir Dis, 133 (1986), pp. 423-430
[24.]
D.A. Rouse, S.L. Morris.
Molecular mechanisms of isoniazid resistance in Mycobacterium tuberculosis and Mycobacterium bovis.
Infect Immunol, 63 (1995), pp. 1427-1433
[25.]
Microbiology Ad Hoc Committee on the Scientific Assembly on, Tuberculosis, and Pulmonary Infections.
Treatment of tuberculosis and tuberculosis infection in adults and children.
Am J Respir Crit Care Med, 149 (1994), pp. 1359-1374
[26.]
Diseases International Union Against Tuberculosis and Lung.
Committee of Treatment.
Bul Int Union Tuberc Lung Dis, 63 (1988), pp. 64-72
[27.]
M.C. Becerra, J. Bayona, J. Freeman, P.E. Farmer, J.Y. Kim.
Redefining MDR-TB transmission ?hot spot'.
Int J Tuberc Lung Dis, 4 (2000), pp. 387-394
[28.]
P. March.
La transmisión de la resistencia al Mycobacterium tuberculosis en los infectados por el VIH. La llamada tercera epidemia del VIH.
Med Clin (Barc), 102 (1994), pp. 98-100
[29.]
G. Canetti, B. Kreis, R. Thibier, P.H. Gay, M. Le Lirzin.
Données actuelles sur la résistance primaire dans la tuberculose pulmonaire de l'adulte in France. Deuxième enquète.
Rev Tuberc Pneumol, 31 (1967), pp. 433-474
[30.]
P. March.
Resistencias primarias y secundarias a las drogas antituberculosas.
Revista IBYS, 28 (1970), pp. 137-174
[31.]
P.D.O. Davies.
Tuberculosis in the United States.
Am Rev Respir Dis, 147 (1993), pp. 497
[32.]
J.A. Caminero.
Situación actual de la tuberculosis en España.
Arch Bronconeumol, 30 (1994), pp. 371-374
[33.]
P. March, J.L. López-Sanmartín, G. Smidt, T. Seix.
Epidemiological significance of primary resistance in Spain. Refutation of the concept on transmission of resistant strains of Mycobacterium tuberculosis.
Chest, 72 (1977), pp. 683-684
[34.]
K. Styblo.
Epidemiology of tuberculosis.
Royal Netherlands Tuberculosis Association Selected Papers,
[35.]
Society American Thoracic.
Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children.
Am J Respir Crit Care Med, 161 (2000), pp. 1371-1395
[36.]
G. Middlebrook.
INH resistance and catalase activity of the tubercle bacilli.
Am Rev Tuberc, 69 (1954), pp. 471-472
[37.]
M.L. Cohn, U. Oda, C. Kovitz, G. Middlebrook.
Studies on isoniazid and tubercle bacilli: the isolation of isoniazid-resistant mutants in vitro.
Am Rev Tuberc, 70 (1954), pp. 465-475
[38.]
M.L. Cohn, C. Kovitz, U. Oda, G. Middlebrook.
Studies on isoniazid and tubercle bacilli: the growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants.
Am Rev Tuberc, 70 (1954), pp. 641-664
[39.]
L.H. Schmidt, A.A. Grover, R. Hoffmann, J. Rehm, R. Sullivan.
The emergence of isoniazid-sensitive bacilli in monkeys inoculated with isoniazid-resistant strains, (1958), pp. 264
[40.]
D.R. Dantzker, N.H. Steinberg, J.E. Kmiecik.
Primary drug-resistant tuberculosis in Vietnam Veterans 1967 to 1970.
Am Rev Respir Dis, 106 (1972), pp. 273-274
[41.]
E.T. Etzkorn, P.K. Lillis, C.K. McAllister.
Tuberculosis in Korea. The relationship between prior therapy and drug resistance.
Chest, 90 (1986), pp. 247-250
[42.]
P. Steiner, M. Rao, M.S. Victoria, J. Hunt, M. Steiner.
A continuing study of primary drug-resistant tuberculosis among children observed at the Kings County Hospital Medical Center between the years 1961 and 1980.
Am Rev Respir Dis, 128 (1983), pp. 425-428
[43.]
D.E. Snider, G.D. Kelly, N.J. Thompson, J.D. Kilburn, R.C. Good.
Infectiousness and pathogenicity of drug resistant Mycobacterium tuberculosis.
Am Rev Respir Dis, 123 (1981), pp. 254-255
[44.]
G.A. Adler, P. Lynne-Davies, J.P. Truant, B.F. Muller.
Primary drug resistant in tuberculosis.
Am Rev Respir Dis, 123 (1981), pp. 256-258
[45.]
A.E. Pitchenik, J. Burr, M. Laufer, G. Miller, R. Cacciatore, W.J. Bigler, et al.
Outbreaks of drug-resistant tuberculosis at AIDS centre.
Lancet, 336 (1990), pp. 400-401
[46.]
Centers for Disease Control.
Nosocomial transmission of multidrug- resistant tuberculosis to health care workers and HIV-infected patients in an urban hospital – Florida.
Mmwr, 39 (1990), pp. 718-772
[47.]
Centers for Disease Control.
Nosocomial transmission of multidrug- resistant tuberculosis among HIV-infected persons – Florida and New York, 1988-1991.
Mmwr, 40 (1991), pp. 585-591
[48.]
B.R. Edlin, J.I. Tokars, M.H. Grieco, J.T. Crawford, J. Williams, E.M. Dordillo, et al.
An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome.
N Engl J Med, 326 (1992), pp. 1514-1521
[49.]
D.E. Snider, W.L. Roper.
The new tuberculosis.
N Engl J Med, 326 (1992), pp. 703-705
[51.]
S.W. Dooley, W.R. Jarvis, W.J. Martone, D.E. Snider.
Multidrug-resistant tuberculosis.
Ann Intern Med, 117 (1992), pp. 257-259
[52.]
J. Glassroth.
Tuberculosis in the United States. Looking for a silver lining among the clouds.
Am Rev Respir Dis, 146 (1992), pp. 278-279
[53.]
H.L. Rieder.
Misbehaviour of a dying epidemic: a call for less speculation and better surveillance.
Tuberc Lung Dis, 73 (1992), pp. 181-183
[54.]
J.M. Watson.
Tuberculosis in Britain today. Notifications are no longer falling.
Br Med J, 306 (1993), pp. 221-222
[56.]
A. Bromberg, R. Bromberg, S. Bonk, L. Tick, B. Hanna, W.N. Rom.
The third epidemic: drug resistant tuberculosis.
Am Rev Respir Dis, 145 (1992), pp. A185
[57.]
Control Centers for Disease.
National action plan to combat multidrug- resistant tuberculosis.
Mmwr, 41 (1992), pp. 5-8
[58.]
Control Center of Disease.
Meeting the challenge of multidrugresistant tuberculosis: summary of a conference.
Mmwr, 41 (1992), pp. 51-57
[59.]
M.A. Fischt, G.L. Daikos, R.B. Uttamchandani, R.B. Poblete, J.N. Moreno, R.R. Reyes, et al.
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.
Ann Intern Med, 117 (1992), pp. 177-183
[60.]
C. Beck-Sagué, S.W. Dooley, M.D. Hutton, J. Otten, A. Breeden, J.T. Crawford, et al.
Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.
Jama, 268 (1992), pp. 1280-1286
[61.]
M.L. Pearson, J.A. Jereb, T.R. Frieden, J.T. Crawford, B.J. Davis, S.W. Dooley, et al.
Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers.
Ann Intern Med, 117 (1992), pp. 191-196
[62.]
Control Center for Disease.
Management of persons exposed to multidrug-resistant tuberculosis.
Mmwr, 41 (1992), pp. 61-71
[63.]
D. Menzies, A. Fanning, L. Yuan, M. Fitzgerald.
Tuberculosis among health care workers.
N Engl J Med, 332 (1995), pp. 92-98
[64.]
P.M. Small, R.W. Shafer, P.C. Hopewell, S.P. Singh, M.J. Murphy, E. Desmond, et al.
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection.
N Engl J Med, 328 (1993), pp. 1137-1144
[65.]
L. Clancy.
Transmisibilidad de la tuberculosis.
Bol Union Int Tuberc Enf Respir, 65 (1990), pp. 77-78
[66.]
R.L. Riley, C.C. Mills, F. O'Grady, L.U. Sultan, F. Wittsadt, D.N. Shivpuri.
Infectiousness of air tuberculosis ward.
Am Rev Respir Dis, 85 (1962), pp. 511-525
[67.]
J.r. Snider DE, G.D. Kelly, G.M. Cauthen, N.J. Thompson, J.O. Kilburn.
Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli.
Am Rev Respir Dis, 132 (1985), pp. 125-132
[68.]
D. Edwards, C.H. Kirkpatrick.
The immunology of mycobacterial diseases.
Am Rev Respir Dis, 134 (1986), pp. 1062-1071
[69.]
A.M. Dannenberg.
Immune mechanisms in the pathogenesis of pulmonary tuberculosis.
Rev Infect Dis, 11 (1989), pp. S369-S378
[70.]
A. Telenti, P. Imboden, F. Marchesi, T. Schmidheini, T. Bodmer.
Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis.
Antimicrob Agents Chemother, 37 (1993), pp. 2054-2058
[71.]
H. Ohno, H. Koga, T. Kuroita, K. Tomono, K. Ogawa, K. Yanagihara, et al.
Rapid prediction of rifampin susceptibility of Mycobacterium tuberculosis.
Am J Respir Crit Care Med, 155 (1997), pp. 2057-2063
[72.]
S. Morris, G. Bai, P. Suffys, L. Portillo-Gomez, M. Fairchok, D. Rouse.
Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis.
J Infect Dis, 171 (1995), pp. 954-960
[73.]
D.L. Williams, C. Waguespack, K. Eisenach, J.T. Crawford, F. Portaels, M. Salfinger, et al.
Characterization of rifampin-resistance in pathogenic mycobacteria.
Antimicrob Agents Chemother, 38 (1994), pp. 2380-2386
[74.]
V. Kapur, L. Li, S. Iordanescu, M.R. Hamrick, A. Wanger, B.N. Kreiswirth, et al.
Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.
J Clin Microbiol, 32 (1994), pp. 1095-1098
[75.]
Y. Zhang, B. Heym, B. Allen, D. Young, S. Cole.
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.
Nature, 358 (1992), pp. 591-593
[76.]
C.L. Kelley, D.A. Rouse, S.L. Morris.
Analysis of aphC gene mutations in isoniazid-resitant clinical isolates of Mycobacterium tuberculosis.
Antimicrob Agents Chemother, 41 (1997), pp. 2057-2058
[77.]
S. Sreevatsan, X. Pan, Y. Zhang, V. Deretic, J.M. Musser.
Analysis of the oxyR-ahpC region isoniazid resistant and ?susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities.
Antimicrob Agents Chemother, 41 (1997), pp. 600-606
[78.]
K. Mdluli, R.A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, et al.
Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
Science, 280 (1998), pp. 1607-1610
[79.]
A. Telenti, N. Honore, C. Bernasconi, J. March, A. Ortega, B. Heym, et al.
Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level.
J Clin Microbiol, 35 (1997), pp. 719-723
[80.]
J.A. Caminero.
Transmisibilidad y patogenia de la tuberculosis multirresistente. XIV Congreso Centroamericano y del Caribe de Neumología.
Managua, Nicaragua, 15 de marzo de, (2000),
[81.]
Ministerio de Sanidad y Consumo. Grupo de trabajo sobre tuberculosis.
Consenso nacional para el control de la tuberculosis en España.
Med Clin (Barc), 98 (1992), pp. 24-31
[82.]
American Thoracic Society.
Centers for Disease Control. Treatment of tuberculosis and tuberculosis infection in adults and children.
Am J Respir Crit Care Med, 149 (1994), pp. 1359-1374
[83.]
D.A. Enarson, H.L. Rieder, T. Arnadottir, A. Trebucq.
Guía de la tuberculosis para los países de escasos recursos económicos.
Unión Internacional contra la Tuberculosis y Enfermedades Respiratorias. París,, 4.a,
[84.]
Organización Mundial de la Salud.
Tratamiento de la tuberculosis. Guía para programas nacionales. Ginebra, 2.a,
[85.]
M.T. Valenzuela, P. García, J. Ponce, R. Lepe, M. Velasco, S. Piffardi.
Drug resistance of M. tuberculosis in Chile: rates of initial resistance for 1986 and acquired resistance for 1985.
Bull Int Union Tuberc Lung Dis, 64 (1989), pp. 13-14
[86.]
P. Chaulet.
Tuberculose et transition épidemiologique: le cas de l'Algerie.
Ann Inst Pasteur, 4 (1993), pp. 181-187
[87.]
P.I. Fujiwara, C. Larkin, T.R. Frieden.
Directly observed therapy in New York City: history, implementation, results, and challenges.
Clin Chest Med, 18 (1997), pp. 135-148
[88.]
A. Marrero, J.A. Caminero, R. Rodríguez, N.E. Billo.
Towards elimination of tuberculosis in a low income country: the experience of Cuba, 1962-1997.
Thorax, 55 (2000), pp. 39-45
[89.]
K. Styblo, D. Dankova, J. Drapela, J. Galliova, Z. Jezek, J. Krivanek, et al.
Epidemiological and clinical study of tuberculosis in the district of Kolin, Czechoslovakia: report for the first 4 years of the study, 1961-64.
Bull World Health Org, 37 (1967), pp. 819-874
[90.]
C.P. Chaulk, K. Moore-rice, R. Rizzo, R.E. Chaisson.
Eleven years of community-based directly observed therapy for tuberculosis.
Jama, 274 (1995), pp. 945-951
[91.]
S.E. Weiss, P.C. Slocum, F.X. Blais, B. King, M. Nunn, G.B. Matney, et al.
The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis.
N Engl J Med, 330 (1994), pp. 1179-1184
[92.]
World Health Organization.
Tuberculosis programme.
Framework for effective tuberculosis control,
[93.]
J.A. Caminero, J.M. Pavón, F. Rodríguez de Castro, F. Díaz, G. Julià, J.A. Caylà, et al.
Evaluation of a directly observed six month fully intermittent treatment regimen for tuberculosis in patients suspected of poor compliance.
Thorax, 51 (1996), pp. 1130-1133
[94.]
Anónimo.
The promise and reality of fixed dose combinations with rifampin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization.
Tuberc Lung Dis, 75 (1994), pp. 180-181
[95.]
D.L. Coombs, L.J. Geiter, R.J. O'Brien.
The UHPS tuberculosis short-course chemotherapy trial 21: effectiveness, toxicity, and acceptability. The report of final results.
Ann Intern Med, 112 (1990), pp. 397-406
[96.]
Singapore Tuberculosis Service/British Medical Research Council.
Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-months regimens for smear-positive pulmonary tuberculosis.
Am Rev Respir Dis, 143 (1991), pp. 707-712
[97.]
T. Moulding, A.K. Dutt, L.B. Reichman.
Fixed-dose combinations of antituberculous medications to prevent drug resistance.
Ann Intern Med, 122 (1995), pp. 951-954
[98.]
G. Acocella.
Human bioavailability studies.
Bull Int Union Tuberc Lung Dis, 64 (1989), pp. 38-40
[99.]
M.W. Uplekar, S. Rangan.
Private doctors and tuberculosis control in India.
Tuberc Lung Dis, 74 (1993), pp. 332-337
[100.]
J.E. Olle-Goig, J.E. Cullity, R. Vargas.
A survey of prescribing patterns for tuberculosis treatment amongst doctors in a Bolivian city.
Int J Tuberc Lung Dis, 3 (1999), pp. 74-78
[101.]
J.A. Caminero.
Estado actual de los programas de control de la tuberculosis en España e Hispanoamérica,
Copyright © 2001. Sociedad Española de Neumología y Cirugía Torácica
